t(4;17)(q12;q21) FIP1L1/RARA

Adriana Zamecnikova

Kuwait Cancer Control Center, Dep of Hematology, Laboratory of Cancer Genetics, Kuwait (AZ)

Published in Atlas Database: October 2014

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0417q12q21ID1470.html
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62124/10-2014-t0417q12q21ID1470.pdf
DOI: 10.4267/2042/62124

This article is an update of : Buijs A, Bruin M. t(4;17)(q12;q21). Atlas Genet Cytogenet Oncol Haematol 2008;12(5)

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on t(4;17)(q12;q21) FIP1L1/RARA, with data on clinics, and the genes implicated.

Clinics and pathology

Disease

Juvenile myelomonocytic leukemia (JMML) and acute promyelocytic leukemia (APL)

Epidemiology

Only 3 cases reported: a 1 year old male patient with JMML (Buijs and Bruin, 2007) and 2 females aged 77 and 90 years diagnosed with APL (Kondo et al., 2008; Menezes et al., 2011).

Evolution

Sole anomaly at diagnosis in a JMML patient that evolved to complex karyotype at relapse: 45,XY,-4,t(4;17)(q12;q21), add(5)(p15),del(7)(q22), -9, -16, -17, +3mar[19]/46,XY[5].

Karyotype of patients with APL: 47,XX,t(4;17)(q12;q21),+8 (Menezes et al., 2011) and 44,X,add(X)(p?),-2,t(4;17)(q12;q21),-4,-16 (Kondo et al., 2008).

Prognosis

Unknown, as only rare cases reported. The patient with JMML succumbed after two SCT. In patients with APL, FIP1L1-RARA had an ATRA response similar to that of PML-RARA.

Cytogenetics

Partial GTG-banded karyotype of t(4;17)(q12;q21).

Morphology of JMML. Bone marrow smears were stained with May-Grünwald-Giemsa and shown at 1000-fold magnification. Bd=band, Bl=myelomonoblast, Eb=erythroblast, Mc=myelocyte, Mo=monocyte, Pm=promyelocyte, Se=segmented neutrophilic granulocyte.
Variants

In APL, 17q21 RARA frequent rearrangement in: t(15;17)(q22;q21), fused with PML; in related translocations, rarely observed, involve a common breakpoint in 17q21, within RARA, fused with different partners, in: t(11;17)(q23;q21), fusion with PLZF, t(5;17)(q35;q12), fusion with NPM1, in t(11;17)(q13;q21), fusion with NUMA and in dup(17)(q12q21), fusion with Stat5b. In myeloproliferative disease CEL (Chronic eosinophilic leukemia) 4q12 FIP1L1 rearrangement: fusion to PDGFRA due to 800 Kb interstitial deletion.

Result of the chromosomal anomaly

Hybrid gene

Description
In-frame fusion of exon 15 of FIP1L1 to exon 3 of RARA (Buijs and Bruin, 2007; Kondo et al., 2008) or with exon 13 of the FIP1L1 gene (Menezes et al., 2011).

Transcript
5′FIP1L1-3′RARA and 5′RARA-3′FIP1L1.

Fusion protein

Description
The fusion mRNA would encode a 832 amino acids FIP1L1/RARA chimeric protein containing the 428 amino-terminal amino acids of FIP1L, including the FIP homology domain and 403 carboxyl-terminal amino acids of RARA, including the DNA and ligand binding domains, with replacement of FIP1L1 amino acid 429 (Valine) and RARA amino acid 60 (Threonine) into an Alanine.

Oncogenesis
All known chimeric RARA fusion proteins provide additional homodimerization motifs, promoting formation of chimeric homodimers and thereby removing requirement of RXR for RARA to bind DNA.
The homodimerization ability of RARA fusion proteins is critical for leukemic transformation. Recently, it was shown in a murine system that retroviral transduced FIP1L1/PDGFRα mediated transformation in vitro and in vivo, is FIP1L1 independent and results from disruption of the autoinhibitory JM domain of PDGFRA. However, observations using retroviral transduced FIP1L1/PDGFRα and FIP1L1/PDGFRα with an N-terminal deletion of the FIP1L1 moiety showed differences with respect to cytokine-independent colony formation and activation of multiple signalling pathways in human primary hematopoietic precursor cells, indicating that FIP1L1 contributes to FIP1L1/PDGFRα resulting in a myeloproliferative phenotype. Therefore the function of the FIP1L1 moiety remains to be resolved.

**To be noted**

**Note**

We report on reciprocal FIP1L1/RARA fusion transcripts resulting from a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia (JMML). JMML is a pediatric myeloproliferative disease (MPD), characterized by proliferation of granulocytic and monocytic lineages. 17q12 RARA was demonstrated to be involved in t(15;17)(q22;q21), resulting in a PML/RARA fusion transcript. PML/RARA t(15;17) is the hallmark of acute promyelocytic leukemia (APL), characterized by a differentiation arrest of abnormal promyelocytes. Variant rearrangements involving 17q21 RARA in APL and APL-like (APL-L) disease are PLZF/RARA t(11;17)(q23;q21), NPM1/RARA t(5;17)(q35;q21), NUMA/RARA t(11;17)(q13;q21), STAT5b/RARA der(17) and t(3;17)(q25;p21). 4q12 FIP1L1 is fused to PDGFRA as a result of a del(4)(q12q12) in myeloproliferative disorder CEL.

**References**

Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J. Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRA and is FIP1L1-independent. Proc Natl Acad Sci U S A. 2006 May 23;103(21):8078-83

Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007 May;21(5):1104-8

Foster DA. Regulation of mTOR by phosphatidic acid? Cancer Res. 2007 Jan 1;67(1):1-4

Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008 Sep;93(9):1414-6


*This article should be referenced as such:*